The European Commission has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide drug, Ozempic, as a treatment for adults with Type II diabetes.
The GLP-1 analogue’s label in Europe recommends that the drug be prescribed when metformin is contraindicated or not tolerated, Novo Nordisk reported today.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk’s once-weekly Type II diabetes med approved in Europe appeared first on MassDevice.
from MassDevice http://ift.tt/2Exk7lx
Cap comentari:
Publica un comentari a l'entrada